araag2/HINT huggingface dataset:
Clinical trial NCT02072434 (phase 3, status: completed)
Conditions: atrial fibrillation
ICD codes: I48.0, I48.21, I48.91, I48.11, I48.19, I48.20
Drugs: edoxaban, warfarin, enoxaparin
SMILES: CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1, S1SSSSSSS1, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Has signed informed consent

          -  Is older than minimum legal adult age (country specific)

          -  Has had ongoing AF lasting at least 48 hrs but <= 12 months (with or without valvular
             heart disease)

          -  Has treatment plan that includes for electrical cardioversion

          -  Has NVAF or other specific valvular heart diseases (eg, mitral valve prolapse, mitral
             valve regurgitation, and aortic valve disease)

        Exclusion Criteria:

          -  Has AF that is transient or reversible

          -  Has contraindicated condition, ie, conditions considered to be formal indication for
             conventional anticoagulation

          -  Has a history of left atrial appendage (LAA) closure

          -  Has a known thrombus in LAA, the left atrial, left ventricle or aorta - or an
             intracardial mass

          -  Has had myocardial infarction (MI), stroke, acute coronary syndrome (ACS), or
             percutaneous coronary intervention (PCI) within the past 30 days

          -  Has any contraindication to anticoagulant agents

          -  Has had protocol-defined signs of bleeding or conditions associated with high risk of
             bleeding that would preclude participation

          -  Is receiving, or plans to receive during the study period, dual antiplatelet therapy
             (DAPT) or invasive procedures (other than routine endoscopy) in which bleeding would
             be anticipated

          -  Has received prohibited concomitant medication or therapy

          -  Has had protocol-defined signs of bleeding or high

          -  Has inadequate liver, kidney, and blood test results

          -  Received any investigational drug or device within the past 30 days or plans to during
             the study period

          -  Has reproductive potential and does not agree to take proper contraceptive measures

          -  Has active cancer requiring chemotherapy/radiation/major surgery within the next 3
             months

          -  Has significant active concurrent medical illness or infection or life expectancy less
             than 6 months

          -  In the opinion of the investigator, is unlikely to comply with the protocol or
             complete the study, has had drug or alcohol dependence within the past year, or has
             any other condition that might place the participant at increased risk of harm

          -  Is a participant in the United States after January 2015 with creatinine clearance
             (CrCL) greater than 95 mL/minute
Clinical trial NCT02072824 (phase 3, status: completed)
Conditions: partial onset seizures
ICD codes: G40.011, G40.019, G40.001, G40.009
Drugs: pregabalin dose level 1, pregabalin dose level 2, placebo
SMILES: NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject must have 3 partial onset seizures in the month prior to screening.

          -  Subject must have 2 partial onset seizures during the 48 hour baseline phase.

          -  Signed Informed Consent.

          -  On 1-3 stable anti-epileptic drugs at screening.

        Exclusion Criteria:

          -  Primary generalized seizures including clonic, tonic, clonic-tonic, absence, febrile
             seizures, and infantile spasms.

          -  Lennox-Gasteau, BECTS, and Dravet's syndrome.

          -  Status epliepticus within 1 year of screening.

          -  Any change in AED regimen with 7 days of screening.

          -  Progressive structural central nervous system (CNS) lesion or a progressive
             encephalopathy.

          -  Progressive errors of metabolism.
Clinical trial NCT02073656 (phase 3, status: completed)
Conditions: hepatitis c virus, hiv
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2, B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4
Drugs: ldv/sof, rbv
SMILES: CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  HCV RNA ≥ 10,000 IU/mL at screening

          -  HCV genotype 1 or 4

          -  HIV-1 infection

          -  Cirrhosis determination, a fibroscan or liver biopsy may be required

          -  Screening laboratory values within defined thresholds

          -  Use of protocol specified method(s) of contraception if female of childbearing
             potential or sexually active male

        Exclusion Criteria:

          -  Clinically-significant illness (other than HCV or HIV) or any other major medical
             disorder that may interfere with subject treatment, assessment, or compliance with the
             protocol

          -  Current or prior history of clinical hepatic decompensation, hepatocellular carcinoma
             (HCC), or other malignancy (with the exception of certain resolved skin cancers)

          -  Hepatitis B virus (HBV) infection

          -  Pregnant or nursing female

          -  Chronic use of systemically administered immunosuppressive agents
Clinical trial NCT02073682 (phase 3, status: completed)
Conditions: venous thromboembolism (vte), deep vein thrombosis (dvt), pulmonary embolism (pe), cancer
ICD codes: O88.22, O88.23, O88.211, O88.212, O88.213, O88.219, I81, K64.5, I51.3, I67.6, I74.11, I74.5, I74.8, Z86.711, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: edoxaban, dalteparin, low molecular weight heparin
SMILES: CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1, O.O.[Al+3].[Cl-].[Zr+4].NCC([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects with age ≥ 18 years or the otherwise legal lower age according
             to the country of residence;

          -  Confirmed acute lower extremity proximal DVT or PE for which long term treatment with
             low molecular weight heparin (LMWH) is indicated;

          -  Cancer, other than basal-cell or squamous-cell carcinoma of the skin;

          -  Able to provide written informed consent.

        Exclusion Criteria:

          -  Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the
             current (index) episode of DVT and/or PE;

          -  Treatment with therapeutic doses of an anticoagulant other than that used for
             pretreatment of the current (index) VTE episode prior to randomization;

          -  Active bleeding or high risk for bleeding contraindicating treatment with LMWH or
             edoxaban;

          -  Any other contraindication listed in the local labeling of dalteparin, enoxaparin, or
             edoxaban;
Clinical trial NCT02074982 (phase 3, status: completed)
Conditions: chronic plaque type psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: ain457 300 mg, ustekinumab 45/90 mg, placebo secukinumab
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  patients with moderate to severe plaque type psoriasis for at least 6 months before
             randomization

          -  patients eligible for systemic therapy with inadequately controlled psoriasis

        Exclusion Criteria:

          -  forms of sporiasis other than plaque type psoriasis

          -  previous exposure to secukinumab, ustekinumab, or other biologic drugs targeting
             (IL)-17A or IL-17RA

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT02076009 (phase 3, status: active, not recruiting)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: daratumumab, lenalidomide, dexamethasone
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Must have documented multiple myeloma and measurable disease

          -  Must have received at least 1 prior line of therapy for multiple myeloma and achieved
             a response (partial response or better) to at least one prior regimen

          -  Must have documented evidence of progressive disease as defined by the International
             Myeloma Working Group criteria on or after their last regimen

          -  Must have an Eastern Cooperative Oncology Group Performance Status score of 0, 1, or 2

          -  If a participant has received subsequent anticancer therapy (salvage therapy), the
             participant must have a "wash-out period" defined as 2 weeks or 5 pharmacokinetic
             half-lives of the treatment, whichever is longer, before the planned start date of
             daratumumab monotherapy. The only exception is the emergency use of a short course of
             corticosteroids (equivalent of dexamethasone 40 milligram per day for a maximum of 4
             days) before Daratumumab monotherapy

        Exclusion Criteria:

          -  Has received any of the following therapies: daratumumab or other anti-CD38 therapies

          -  Has received anti-myeloma treatment within 2 weeks or 5 pharmacokinetic half-lives of
             the treatment

          -  Disease shows evidence of refractoriness or intolerance to lenalidomide or if
             previously treated with a lenalidomide-containing regimen the participant is excluded
             if he or she discontinued due to any adverse event related to prior lenalidomide
             treatment

          -  Has received autologous stem cell transplantation within 12 weeks before the date of
             randomization, or previously received an allogenic stem cell transplant (regardless of
             timing), or planning to undergo a stem cell transplant prior to progression of disease

          -  History of malignancy (other than multiple myeloma) within 5 years before the first
             dose of daratumumab monotherapy (exceptions are squamous and basal cell carcinomas of
             the skin and carcinoma in situ of the cervix, or breast, or other non-invasive lesion,
             that in the opinion of the investigator, with concurrence with the sponsor's medical
             monitor, is considered cured with minimal risk of recurrence within 5 years)
Clinical trial NCT02079246 (phase 3, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: idalopirdine 60 mg
SMILES: FC(F)C(F)(F)COC1=CC=CC(CNCCC2=CNC3=CC(F)=CC=C23)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  the patient has completed Visit 7 (Completion Visit) in the lead-in double-blind,
             placebo controlled clinical studies 14861A/NCT01955161 or 14862A/NCT02006641

        For patients in the OLEX-MEM:

          -  The patient has completed Visit 6 (Week 28) of the OLEX.

          -  The patient, according to the judgement of the investigator, requires initiation of
             treatment with memantine as per local label/SmPC/treatment guidelines.

        Exclusion Criteria:

          -  The patient has a moderate or severe ongoing adverse event from the lead-in study
             considered a potential safety risk by the investigator.

          -  The patient has experienced seizures before Completion Visit in the lead-in study.

          -  The patient has evidence of clinically significant disease.

          -  The patient's donepezil treatment is likely to be interrupted or discontinued during
             the study.

          -  The patient is receiving therapy with another acetylcholinesterase inhibitors (AChEI).

        Other protocol-defined inclusion and exclusion criteria may apply.
Clinical trial NCT02080364 (phase 3, status: terminated)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: azeliragon, placebo
SMILES: CCCCC1=NC(=CN1C1=CC=C(OC2=CC=C(Cl)C=C2)C=C1)C1=CC=C(OCCCN(CC)CC)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    not due to safety but due to a lack of efficacy at the 5 mg azeliragon dose.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of probable Alzheimer Disease (AD) with documented evidence of progression
             of disease

          -  Mini Mental State Examination (MMSE) score of 21-26, inclusive

          -  Clinical Dementia Rating global score of 0.5 or 1

          -  Rosen-Modified Hachinski Ischemia Score less than or equal to 4

          -  Brain magnetic resonance imaging (MRI) consistent with the diagnosis of probable AD

          -  Concurrent use of cholinesterase inhibitor or memantine with stable dose for at least
             3 months prior to randomization

          -  Caregiver willing to participate and be able to attend clinic visits with patient

          -  Ability to ingest oral medications

        Exclusion Criteria:

          -  Significant neurological or psychiatric disease other than Alzheimer's disease

          -  Participants with evidence or history of severe drug allergies (resulting in dyspnea
             or severe rash).

          -  Any contraindications to MRI (e.g., clinically significant claustrophobia,
             non-removable ferromagnetic implants). Patients with contraindications to MRI may
             undergo computed tomography (CT) on approval by sponsor.

          -  Any contraindications to the FDG-PET study (e.g. allergy to any component of the FDG
             dose) in the cohort undergoing a PET scan.

          -  Previous exposure to investigational or non-investigational therapies for Alzheimer's
             disease within 6 months of screening

          -  History of cancer within the last 5 years except adequately treated cervical carcinoma
             in-situ, cutaneous basal cell or squamous cell cancer, or non-progressive prostate
             cancer not requiring treatment

          -  Women of childbearing potential

          -  Uncontrolled blood pressure and/or blood pressure above 160/100

          -  Prescription medical food intended for dietary management of the metabolic processes
             associated with Alzheimer's disease.

          -  Diagnosis or history of cerebrovascular stroke, severe carotid stenosis, cerebral
             hemorrhage, intracranial tumor, subarachnoid hemorrhage.

          -  Patients with unstable, uncontrolled diabetes (HbA1c > 7.7%) and those requiring
             insulin.
Clinical trial NCT02082522 (phase 3, status: terminated)
Conditions: hilar cholangiocarcinoma
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: photodynamic therapy-photofrin, chemotherapy regimen
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Reason stopped: 
    accrual rate remaining too low
  
Eligibility criteria:

        Inclusion Criteria:

          -  Males or females aged 18 or older

          -  Diagnosed with radiologically and biopsy or cytology confirmed inoperable perihilar
             cholangiocarcinoma Bismuth Tumor Stage III/IV

          -  Non-menopausal or non-sterile female subjects of childbearing potential must have a
             negative serum beta-HCG and use a medically acceptable form of birth control

          -  Able to sign an informed consent

        Exclusion Criteria:

          -  Diagnostic of cholangiocarcinoma made more than 45 days prior to randomization

          -  Cholangiocarcinoma with extra-hepatic metastasis or concurrent non-solid malignancy

          -  Presence or history of other neoplasms (treated during the last five years prior to
             study entry) other than carcinoma in situ of the cervix or basal carcinoma of the skin

          -  Previously received photodynamic therapy for cholangiocarcinoma

          -  Previously undergone surgical resection of the cholangiocarcinoma

          -  Previously undergone chemotherapy, brachytherapy, or radiotherapy prior to entering
             the study

          -  Previously undergone metal stent insertion

          -  Porphyria or hypersensitivity to porphyrins (constituents of porfimer sodium),
             gemcitabine, cisplatin or other platinum-containing compounds

          -  Presence of infection other than the infection of the bile duct (cholangitis)

          -  Acute or chronic medical or psychological illnesses that prevent endoscopy procedures

          -  Abnormal blood test results

          -  Severe impairment of your kidney or liver function

          -  Decompensated cirrhosis

          -  Pregnant or intend to become pregnant, breastfeeding or intend to breast-feed during
             this study

          -  Participated in another drug study within 90 days before this one

          -  Unable or unwilling to complete the follow-up evaluations required for the study
Clinical trial NCT02085135 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: alks 5461
SMILES: CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4
Eligibility criteria:

        Inclusion Criteria:

          -  Body mass index of 18-40 kg/m2

          -  Have a diagnosis of MDD

          -  Have a current major depressive episode (MDE) lasting 8 weeks to 24 months

          -  Have been treated with an adequate dose of an approved antidepressant during the
             current MDE for at least 8 weeks

          -  Have an inadequate response to current antidepressant treatment

          -  Agree to use an approved method of birth control for the duration of the study

          -  Additional criteria may apply

        Exclusion Criteria:

          -  Currently pregnant or breastfeeding

          -  History of or current infection with Hepatitis B Virus, Hepatitis C Virus or Human
             Immunodeficiency Virus (HIV)

          -  Have experienced hallucinations, delusions, or any psychotic symptoms in the current
             MDE

          -  Have used opioid agonists (eg, codeine, oxycodone, tramadol, or morphine) or opioid
             antagonists (eg, naloxone, naltrexone) within 14 days

          -  Have received electroconvulsive therapy treatment within the last 5 years

          -  Have attempted suicide within the past 2 years

          -  Have a history of intolerance, allergy, or hypersensitivity to buprenorphine or opioid
             antagonists (eg, naltrexone, naloxone)

          -  Have had a significant blood loss or blood donation with 60 days of screening

          -  Additional criteria may apply
Clinical trial NCT02088073 (phase 3, status: completed)
Conditions: hyperkalemia
ICD codes: E87.5, P74.31
Drugs: sodium zirconium cyclosilicate, placebo
SMILES: O.O.[Na+].[Na+].O[Si](O)(O)O.O[Si](O)(O)O.O[Si](O)(O)O.O[Zr](O)(O)(O)([O-])[O-], CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Provision of written informed consent.

          -  Over 18 years of age.

          -  Two consecutive i-STAT potassium values, measured 60-minutes apart, both ≥5.1 mmol/l
             and measured within 1 day of the first ZS dose on AP Study Day 1.

          -  Ability to have repeated blood draws or effective venous catheterization.

          -  Women of childbearing potential must be using two forms of medically acceptable
             contraception (at least one barrier method) and have a negative pregnancy test at AP
             Study Day 1. Women who are surgically sterile or those who are post-menopausal for at
             least 2 years are not considered to be of childbearing potential.

        Exclusion Criteria:

          -  Pseudohyperkalemia signs and symptoms, such as excessive fist clenching hemolyzed
             blood specimen, history of severe leukocytosis or thrombocytosis.

          -  Subjects treated with lactulose, Xifaxan or other non-absorbed antibiotics for
             hyperammonemia within 7 days prior to the first dose of study drug.

          -  Subjects treated with resins (such as sevelamer acetate or sodium polystyrene
             sulfonate [SPS; e.g. Kayexalate®]), calcium acetate, calcium carbonate, or lanthanum
             carbonate, within 7 days prior to the first dose of study drug.

          -  Subjects with a life expectancy of less than 3 months.

          -  Subjects who are severely physically or mentally incapacitated and who in the opinion
             of investigator are unable to perform the subjects' tasks associated with the
             protocol.

          -  Women who are pregnant, lactating, or planning to become pregnant.

          -  Subjects with diabetic ketoacidosis.

          -  Presence of any condition which, in the opinion of the investigator, places the
             subject at undue risk or potentially jeopardizes the quality of the data to be
             generated.

          -  Known hypersensitivity or previous anaphylaxis to ZS or to components thereof.

          -  Randomization into the previous ZS-002 or ZS-003 studies.

          -  Treatment with a drug or device within the last 30 days that has not received
             regulatory approval at the time of study entry.

          -  Subjects with cardiac arrhythmias that require immediate treatment.

          -  Subjects on dialysis.
Clinical trial NCT02090764 (phase 3, status: completed)
Conditions: impetigo
ICD codes: L01.00, L01.02, L01.03, L01.09, L01.01
Drugs: ozenoxacin, placebo
SMILES: CNC1=NC=C(C=C1C)C1=CC=C2C(=O)C(=CN(C3CC3)C2=C1C)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of bullous or non bullous impetigo. The patient has a total
             affected area comprised between 1-100 cm2 with surrounding erythema not extending more
             than 2 cm from the edge of any affected area. In case of multiple affected areas the
             total area will be the sum of each affected area and will not exceed 100 cm2.
             Additionally for patients < 12 years the total area will not exceed a maximum of 2% of
             the body surface area.

          -  Total Skin Infection Rating Scale (SIRS) score of at least 3, including pus/exudate
             score of at least 1

        Exclusion Criteria:

          -  Has a bacterial infection, which in the opinion of the investigator, could not be
             appropriately treated by a topical antibiotic.

          -  Has systemic signs and symptoms of infection (e.g. a fever; defined as an axillary
             temperature over 37.2 °C (99.0 °F)